Poland· PL-100370449

Darzalex

A daratumumab product containing daratumumabum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L01FC01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDarzalexATCL01FC01REGISTER NO.PL-100370449PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Daratumumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FC01 (daratumumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Daratumumab · ATC L01FC01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Daratumumabum
Manufacturer
Janssen-Cilag International N.V.
Country
Poland (PL)
ATC code
L01FC01
ATC class
Daratumumab
Defined daily dose
64.3 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991275228
  • gtin
    04150115644678
  • gtin
    05909991275235

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

72 interactions on record for daratumumab.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Daratumumab · interactions on record

72 records

  • 29 severe
  • 43 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Daratumumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All daratumumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Darzalex
  • Liechtenstein · Darzalex
  • Norway · Darzalex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8211178d-f947-4536-80ea-6246717e14b2
GET /v1/drugs/8211178d-f947-4536-80ea-6246717e14b2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "20 mg/ml",
  "packaging": "05909991275228 ¦ Rpz ¦ EU/1/16/1101/001 ¦ 115673\n1 fiol. 5 ml\n¦ UR/Z/4b/144/26 - 04150115644678\n05909991275235 ¦ Rpz ¦ EU/1/16/1101/002 ¦ 115674\n1 fiol. 20 ml\nRpz ¦ EU/1/16/1101/003 ¦ 134525\n5 fiol. 20 ml\nRpz ¦ EU/1/16/1101/003 ¦ 134526\n6 fiol. 5 ml",
  "substance": "Daratumumabum 20 mg/ml",
  "common_name": "Daratumumabum",
  "pl_product_id": "100370449",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about daratumumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.